The drug maker agreed to pay $4.85 billion to settle lawsuits from individuals who say its painkiller Vioxx led to heart attacks and strokes. Predictions put the settlement costs at $25 billion when Vioxx was taken off the market in September 2004.
The J. Craig Venter Institute, along with researchers at MIT and the Center for Strategic and International Studies, recently released a report entitled “Synthetic Genomics | Options for Governance.” But are there larger unanswered questions about the societal impacts of creating synthetic life?
Two companies are about to become the first Embryonic Stem Cell biotech firms to draft FDA applications for human testing. For some time, ESC-research opponents have complained that human trials have involved therapies utilizing adult stem cells, but none have utilized embryonic stem cells.
Science Progress and American Progress's Doing What Works project teamed up to produce a set of policy proposals that the Obama administration and Congress can adopt to reinvest in the building blocks of American science, innovation, and economic competitiveness. Read the overview of the five reports.
Science Progress proceeds from the propositions that scientific inquiry is among the finest expressions of human excellence, that it is a crucial source of human flourishing, a critical engine of economic growth, and must be dedicated to the common good. Scientific inquiry entails global responsibilities. It should lead to a more equitable, safer, and healthier future for all of humankind.